New trial highlights effectiveness of EKOS system in treating pulmonary embolism.
- EKOS system shows superior results for pulmonary embolism treatment.
- Trial suggests new standard for care.
- Most severe cases benefited from the technology.
The Hi-PEITHO trial has demonstrated that the EKOS Endovascular System offers superior treatment outcomes for patients suffering from acute pulmonary embolism compared to standard care practices. This trial, conducted by Boston Scientific, marks a significant advancement in the management of this critical condition. Acute pulmonary embolism is a life-threatening illness characterized by blocked arteries in the lungs.
Findings from the trial suggest that patients treated with the EKOS system experienced improved outcomes, including higher rates of successful thrombus resolution and fewer complications. The study involved multiple sites and included diverse patient populations, reinforcing the reliability of the results. This development may reshape the approach to treating severe cases of pulmonary embolism.
Moreover, the data indicates that using the EKOS Endovascular System could potentially lead to lower healthcare costs and improved patient satisfaction. As healthcare providers evaluate the implications of these results, the EKOS system's role may become more prominent in clinical practice for managing acute pulmonary embolism effectively.
